1294.TWO Hantech Bio-Technology Co., Ltd.
- Market cap
- TWD 1.61B
- P/E
- 12.0x
- P/B
- 2.13x
- ROE
- 19.7%
- Dividend yield
- 5.43%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1294.TWO undervalued?
Graham number1294.TWO trades 6.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hantech Bio-Technology Co., Ltd. fundamental analysis
No fundamental analysis for Hantech Bio-Technology Co., Ltd. yet.
Hantech Bio-Technology Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hantech Bio-Technology Co., Ltd.
Hantech Bio-Technology Co., Ltd., through its subsidiaries, engages in the manufacture, trade in, and distributes biotech foods, health foods, and Traditional Chinese Medicine skincare and beauty products in Taiwan and internationally. The company offers OEM & ODM manufacturer of liquid, jelly, and gel-type health supplements. It also provides aluminum foil bag designs; and aluminum foil-packaged beverage production activities. In addition, the company is involved in the man…
Full company profileHantech Bio-Technology Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hantech Bio-Technology Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 240M | 303M | 625M | 748M | 779M | 911M |
| Gross Profit | 101M | 127M | 281M | 306M | 289M | 321M |
| Operating Income | 38.6M | 57.4M | 185M | 197M | 174M | 199M |
| EBITDA | - | 78.5M | 208M | 232M | 214M | 243M |
| Net Income | 32.6M | 47.5M | 148M | 156M | 139M | 162M |
| EPS | 1.19 | 1.45 | 5.34 | 5.12 | 3.83 | 4.45 |
| Balance Sheet | ||||||
| Total Assets | 376M | 474M | 931M | 1.12B | 1.17B | 1.23B |
| Total Liabilities | 198M | 205M | 530M | 298M | 334M | 405M |
| Shareholders' Equity | 175M | 267M | 398M | 818M | 829M | 819M |
| Cash & Short-term Investments | 86.4M | 75.0M | 167M | 382M | 249M | 264M |
| Cash Flow | ||||||
| Operating Cash Flow | 44.4M | 63.2M | 192M | 151M | 161M | 160M |
| Capital Expenditure | 80.3M | 83.6M | 297M | 25.4M | 16.7M | 48.1M |
| Free Cash Flow | -35.9M | -20.4M | -105M | 125M | 144M | 112M |
| Ratios | ||||||
| ROE | 18.6% | 17.8% | 37.2% | 19.0% | 16.8% | 19.7% |
| ROA | 8.7% | 10.0% | 15.9% | 13.9% | 11.9% | 13.2% |
| Net Profit Margin | 13.5% | 15.7% | 23.7% | 20.8% | 17.9% | 17.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hantech Bio-Technology Co., Ltd. dividends
- Dividend yield
- 5.43%
- Forward dividend
- 3.00 TWD
- Payout ratio
- 62.9%
- Ex-dividend date
- Jul 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 87.4M | 2.41 | 62.9% |
| 2024 | TWD 19.4M | 0.64 | 12.5% |
| 2023 | TWD 16.8M | 0.61 | 11.4% |
| 2022 | - | - | - |
| 2021 | TWD 8.06M | 0.29 | 24.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1200:1000 on Jul 3, 2026.
Who owns Hantech Bio-Technology Co., Ltd.
- Insiders 53.27%
- Institutions 0.00%
- Public & others 46.73%
- Shares outstanding 36.3M
- Free float 15.9M
Hantech Bio-Technology Co., Ltd. company profile
- Company name
- Hantech Bio-Technology Co., Ltd.
- Ticker
- 1294.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Fiscal year end
- December
- Address
- No. 101, Gongye Rd., Changhua, Taiwan, 514
- Phone
- 886 4 881 1181
- Website
- htbios.com
About Hantech Bio-Technology Co., Ltd.
Hantech Bio-Technology Co., Ltd., through its subsidiaries, engages in the manufacture, trade in, and distributes biotech foods, health foods, and Traditional Chinese Medicine skincare and beauty products in Taiwan and internationally. The company offers OEM & ODM manufacturer of liquid, jelly, and gel-type health supplements. It also provides aluminum foil bag designs; and aluminum foil-packaged beverage production activities. In addition, the company is involved in the manufacture of machinery and equipment; and trade in of health food raw materials. It serves clients across both online and offline channels, including direct sales, micro-businesses, physical stores (pharmacies/drugstores/beauty shops), TV, radio, telemarketing centers, TV shopping, online shopping, and live-stream shopping. Hantech Bio-Technology Co., Ltd. was founded in 2007 and is based in Changhua, Taiwan.
Hantech Bio-Technology Co., Ltd. management
6- Xie JunyangChief Financial Officer
- Geng Hao LiuAccounting Supervisor
- Mr. Laien LiDeputy GM of General Administration Office
- Ms. Yuxuan LiChief of Audit Section
- Mr. Qihao LiuTreasurer
- Mr. Bizhen YangDeputy GM of Quality Assurance Department